Tuberculosis (TB) Diagnostics Market Forecasts to 2028 – Global Analysis by Product Types (Detection of Latent Infection, Cytokine Detection Assay, Diagnostic Laboratory Methods, Other Product Types), Test Type (Tuberculin skin tests, Interferon-gamma rel

Tuberculosis (TB) Diagnostics Market Forecasts to 2028 – Global Analysis by Product Types (Detection of Latent Infection, Cytokine Detection Assay, Diagnostic Laboratory Methods, Other Product Types), Test Type (Tuberculin skin tests, Interferon-gamma release assays (IGRAs), Smear microscopy, Other test types), Type (Sputum Smear Microscopy, Rapid Molecular Diagnostics, Other Types), End-user (Diagnostic Laboratories, Hospitals, Other end users), and By Geography

According to Stratistics MRC, the Global Tuberculosis (TB) Diagnostics Market is accounted for $1.84 billion in 2022 and is expected to reach $2.94 billion by 2028 growing at a CAGR of 8.1% during the forecast period. Mycobacterium tuberculosis is a type of bacteria that causes the dangerous disease tuberculosis. The patient's lungs are typically the target of the illness. The infection can also affect the spine and the brain, among other bodily parts. Skin testing and blood tests can be used to diagnose tuberculosis. The necessity for precise and effective diagnostic tests to stop the spread of this condition has increased as its incidence has increased. In the upcoming years, it is anticipated that this factor will dramatically increase demand for tuberculosis tests.

According to the Global Tuberculosis Report 2021 published by the World Health Organization, in October 2021, most of the tuberculosis cases were found in the World Health Organization (WHO) regions of South-East Asia (43%), Africa (25%), and the Western Pacific (18%), and lesser numbers of tuberculosis cases were found in Eastern Mediterranean (8.3%), and Europe (2.3%). According to the data published by the World Health Organization (WHO), in October 2021, about 1.5 million people worldwide died because of tuberculosis (TB), in 2020, and approximately 10 million people fell ill with tuberculosis globally.

Market Dynamics:

Driver:

Favourable Government Policies to Surge the Demand

To lessen the global burden of tuberculosis, governments have strengthened their policies for diagnosis. Over the coming years, there will likely be a rise in the need for diagnoses as awareness of the disease's seriousness grows across all nations. The creation of measures to boost tuberculosis diagnosis rates has received emphasis in several nations. The need for government policies and laws to raise tuberculosis diagnosis rates is further increased by factors such the high prevalence of tuberculosis in countries with large burdens of the disease and the rising demand for TB testing. Additionally, it is anticipated that in the near future, sales of TB diagnostics would increase significantly due to growing awareness in high-TB burden nations where the main goal is to reduce tuberculosis cases.

Restraint:

Limitations of Existing Tuberculosis (TB) Diagnostics

Despite the urgent and growing need for better diagnostics for various diseases, there are a few obstacles that could prevent the market from expanding throughout the projected period. For instance, during the projected period, some technical challenges related to tuberculosis diagnostics may significantly constrain the market. One of the main factors preventing the market from expanding more broadly is the greater level of technical difficulties in establishing these diagnostic technologies.

Opportunity:

Rising Incidence of Tuberculosis in High Burden Countries

The huge rise in this disease's occurrence in emerging nations is one of the most important factors that is positively affecting the market's expansion. For instance, the number of patients with tuberculosis has increased significantly during the past few decades. In order to improve patient outcomes and boost the precision of these diagnoses, this element generated demand for research into efficient diagnostic technology.

Threat:

High costs associated with tuberculosis diagnostics

Some of the challenges impeding market expansion during the projection period include the high costs associated with tuberculosis tests and the lack of insurance coverage in emerging markets. Patients may incur catastrophic costs as a result of their TB. For patients, income loss frequently represents the biggest financial risk. TB patients and their families need to get appropriate income replacement and other social protection interventions, in addition to making sure that healthcare services are equitably funded and provided in a way that reduces direct and indirect expenses.

Covid-19 Impact:

During the COVID-19 pandemic, there was a decrease in the need for tuberculosis diagnostic products. This element was brought on by the sharp fall in the number of patients diagnosed with TB. Compared to the previous year, the growth of the global market shrank. The incidence of TB testing decreased in the high-burden areas of the worldwide market as a result of the COVID-19 pandemic. Despite the disease's high level of infectiousness, during the early stages of the pandemic, funding for initiatives to diagnose tuberculosis was diverted to combat the coronavirus pandemic.

The rapid molecular diagnostics is expected to be the largest during the forecast period

During the projection period, new product launches in the rapid molecular diagnostics market are also predicted to further fuel the segment's expansion. The market leader and predicted to continue to have a sizeable market share is the rapid molecular diagnostics sector. Rapid molecular diagnostics for TB detection are credited with the efficiency and accuracy that have led to the segment's rise. Rapid molecular diagnostics for TB detection are credited with the efficiency and accuracy that have led to the segment's rise.

The diagnostic laboratories segment is expected to have the highest CAGR during the forecast period

The market is divided into diagnostic laboratories and hospitals based on the end user. During the forecast period, the market's highest CAGR growth rate was accounted for by the diagnostic laboratories sector. The category is expanding as a result of the widespread use of diagnostic laboratories. The category is expanding as a result of an uptick in the number of TB diagnoses performed in these diagnostic labs. The category is expanding as a result of an uptick in the number of TB diagnoses performed in these diagnostic labs.

Region with highest share:

Due to factors including the rising tuberculosis incidence in the region, the presence of a well-established healthcare infrastructure, and high healthcare spending, North America is predicted to hold largest share in the tuberculosis diagnostic market. The primary reason fueling the market's expansion is the increased prevalence of tuberculosis in the area. Additionally, it is anticipated that the company's efforts to produce cutting-edge medicines would increase in response to the region's rising healthcare spending, fueling the market's expansion.

Region with highest CAGR:

During the forecast period, the market in Asia Pacific is anticipated to experience a high CAGR. The Asia Pacific market is growing at a faster rate than other regions due to improvements in healthcare infrastructure, a high prevalence of TB disease, and rising consumer desire for better treatment outcomes.

Key players in the market

Some of the key players in Tuberculosis (TB) Diagnostics market include Becton, Dickinson and Company, Abbott Laboratories, Siemens, Hologic Corporation, Cepheid, BioMérieux SA, Hain Life sciences GmBH, F.Hoffmann-La Roche AG, Alere, Inc., F. Hoffmann-La Roche Ltd (Switzerland), Thermo Fisher Scientific Inc. (U.S.), QIAGEN (Netherlands), Hain Life science GmbH, Oxford Immunotec USA, Inc., Akonni Biosystems, Inc., Epistem Ltd., Johnson & Johnson Services, Inc., Novartis AG, GlaxoSmithKline PLC, PerkinElmer Inc.

Key Developments:

In May 2022, F. Hoffmann-La Roche Ltd entered into a partnership with the Global Fund to support low and middle-income countries in strengthening critical diagnosis infrastructure against infectious diseases.

In March 2022, Thermo Fisher Scientific Inc. launched the SeqStudio Flex Series Genetic Analyzer for research and development of infectious disease detection, which is expected to expand the company's product portfolio in the market.

In February 2022, QIAGEN announced that its Quanti FERON tuberculosis testing solution received the approval of the fourth generation of a modern gold standard test in China.

In July 2021, F. Hoffmann-La Roche Ltd. announced that WHO included the company’s products cobas MTB and cobas MTB-RIF/INH tests as Nucleic Acid Amplification Tests Go (NAATs). These products are nucleic acid testing products used to detect tuberculosis and drug resistance TB.

In March 2021, Hologic, Inc. announced the CE marking of its tuberculosis (TB) IGRA test on VIDAS. VIDAS TB-IGRA is an automated assay that helps in the diagnosis of infection with Mycobacterium tuberculosis.

Products Covered:
• Detection of Latent Infection
• Cytokine Detection Assay
• Diagnostic Laboratory Methods
• Nucleic Acid Testing
• Detection of Drug Resistance
• Radiographic Method
• Other Product Types

Test Types Covered:
• Wet Tuberculin skin tests
• Interferon-gamma release assays (IGRAs)
• Smear microscopy
• Serological antibody-based tests
• Culture
• Identification or speciation tests
• Nucleic acid amplification tests (NAATs)
• Phenotypic drug susceptibility tests
• Adenosine deaminase (ADA) test.

Types Covered:
• Sputum Smear Microscopy
• Rapid Molecular Diagnostics
• Culture-based Diagnostics
• Other Types

End Users Covered:
• Diagnostic Laboratories
• Hospitals
• Clinics
• Reference Laboratories
• Research Institutes and Academics
• Other End Users

Regions Covered:
• North America
US
Canada
Mexico
• Europe
Germany
UK
Italy
France
Spain
Rest of Europe
• Asia Pacific
Japan
China
India
Australia
New Zealand
South Korea
Rest of Asia Pacific
• South America
Argentina
Brazil
Chile
Rest of South America
• Middle East & Africa
Saudi Arabia
UAE
Qatar
South Africa
Rest of Middle East & Africa

What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2020, 2021, 2022, 2025, and 2028
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements